The Roles of Alternative Splicing in Tumor-immune Cell Interactions

Author(s): Yue Wang, Honglei Zhang*, Baowei Jiao*, Jianyun Nie*, Xiyin Li, Wenhuan Wang, Hairui Wang

Journal Name: Current Cancer Drug Targets

Volume 20 , Issue 10 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Alternative splicing (AS) plays a significant role in the hallmarks of cancer and can provide neoantigens for immunotherapy. Here, we summarize recent advances in immune system associated tumor specific-antigens (TSAs) produced by AS. We further discuss the regulating mechanisms involved in AS-mediated innate and adaptive immune responses and the anti-tumoral and protumoral roles in different types of cancer. For example, ULBP1_RI, MLL5Δ21spe, NKp44-1Δ5, MHC-IΔ7, CD200SΔ1, 2, PVR α/β/γ/δ and IL-33 variants 1/2/3 act as regulators in solid tumors and IPAK4-L and, FOXP1ΔN100 exhibit functions in hematological cancers.

Keywords: Alternative splicing, tumor cells, immune system, immunotherapy, neoantigens, Tumor specific-antigens (TSAs).

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 02 November, 2020
Page: [729 - 740]
Pages: 12
DOI: 10.2174/1568009620666200619123725

Article Metrics

PDF: 21